jungle jim's semaglutide Jims Compounding Pharmacy Compounded Semaglutide (GLP-1)

doi: 10.1097/00004836-199700001-00029 97 WallaschekNReuterSSilkenatSWolfKNiklasCKayisogluOet al

Molecular Identity Developer Eli Lilly Mechanism Triple GLP-1, GIP, and glucagon receptor agonist FDA Status Under regulatory review (Phase 3 complete) Administration Weekly subcutaneous Triple-Agonist Mechanism Retatrutide combines all pathways: GLP-1: Core incretin signaling (shared with both Mazdutide and Tirzepatide) GIP: Second incretin pathway (shared with Tirzepatide, absent in Mazdutide) Glucagon: Hepatic energy expenditure (shared with Mazdutide, absent in Tirzepatide) For research examining the contributions of all three pathways, Retatrutide provides comprehensive coverage

10 , e2206007 (2023)

A big appreciation to the entire team and individuals who contributed to making this possibletruly inspiring

Here we focus on three that affect cognitive function